| Literature DB >> 21228077 |
Michelle M Graham1, William A Ghali, Danielle A Southern, Mouhieddin Traboulsi, Merril L Knudtson.
Abstract
BACKGROUND: Primary percutaneous coronary intervention (PCI) is a proven therapy for acute ST-segment elevation myocardial infarction. However, outcomes associated with primary PCI may differ depending on time of day. METHODS ANDEntities:
Mesh:
Year: 2011 PMID: 21228077 PMCID: PMC3022364 DOI: 10.1136/bmjqs.2010.041137
Source DB: PubMed Journal: BMJ Qual Saf ISSN: 2044-5415 Impact factor: 7.035
Baseline Characteristics
| After hours (n=906) | Working hours (n=758) | p Value | |
| Clinical characteristics | |||
| Mean age (SD), years | 60.3 (13.2) | 61.5 (12.7) | 0.07 |
| Sex (% female) | 22.2 | 26.0 | 0.07 |
| Ejection fraction (%) | 0.08 | ||
| <35 | 6.9 | 6.9 | |
| 35–50 | 29.9 | 29.2 | |
| >50 | 49.9 | 47.2 | |
| LV not done | 10.7 | 14.6 | |
| Missing | 2.5 | 2.1 | |
| Congestive heart failure (%) | 11.9 | 10.6 | 0.38 |
| Peripheral vascular disease (%) | 4.4 | 4.0 | 0.64 |
| Chronic pulmonary disease (%) | 6.8 | 9.4 | 0.06 |
| Cerebrovascular disease (%) | 4.5 | 4.2 | 0.76 |
| Creatinine >200 mmol/l (%) | 4.0 | 2.5 | 0.09 |
| Dialysis dependent (%) | 1.0 | 0.5 | 0.29 |
| Diabetes (%) | 15.9 | 15.7 | 0.91 |
| Hypertension (%) | 50.0 | 47.9 | 0.39 |
| Hyperlipidaemia (%) | 45.8 | 45.4 | 0.86 |
| Liver/gastrointestinal disease (%) | 2.7 | 3.4 | 0.35 |
| Malignancy (%) | 3.0 | 2.9 | 0.92 |
| Previous coronary artery bypass grafting (CABG) (%) | 1.8 | 1.3 | 0.46 |
| Previous myocardial infarction (MI) (%) | 10.7 | 13.7 | 0.06 |
| Previous percutaneous coronary intervention (PCI) (%) | 3.5 | 3.7 | 0.86 |
| Procedural characteristics | |||
| Coronary anatomy (%) | 0.79 | ||
| One-vessel disease | 38.5 | 38.9 | |
| Two-vessel disease | 31.0 | 29.0 | |
| Three-vessel disease | 26.6 | 28.4 | |
| Left main | 3.9 | 3.7 | |
| Vessel intervened (%) | 0.77 | ||
| Right coronary | 44.4 | 44.6 | |
| Circumflex | 12.9 | 14.0 | |
| Left anterior descending | 42.4 | 41.0 | |
| Left mainstem | 0.3 | 0.3 | |
| Saphenous vein graft | 0.0 | 0.1 | |
| Glycoprotein IIb/IIIa inhibitor (%) | 73.2 | 74.7 | 0.49 |
| Stent use (%) | 92.3 | 90.5 | 0.20 |
| Intra-aortic balloon pump (IABP, %) | 6.1 | 11.6 | <0.0001 |
| Inotrope use (%) | 2.4 | 1.1 | 0.036 |
| IABP+inotrope (%) | 7.6 | 12.0 | 0.003 |
Figure 1Kaplan–Meier survival curves to 1 year for primary percutaneous coronary intervention (PCI) performed after hours and during regular working hours.
Crude and Adjusted Hazard Ratio for survival for after-hours relative to regular hours primary PCI
| Crude HR (95% CI) | HR-1 adjusted | Adjusted HR-2 | |
| 30-day survival | 1.34 (0.85 to 2.12) | 1.26 (0.78 to 2.02) | 1.23 (0.77 to 1.99) |
| 1-year survival | 1.18 (0.81 to 1.72) | 1.08 (0.73 to 1.59) | 1.06 (0.71 to 1.56) |
HR-1 adjusted for all variables in table 1.
HR-2 adjusted for variables in table 1 plus door-to-balloon time.
Figure 2Boxplots illustrating door-to-balloon times for primary percutaneous coronary intervention performed after hours and during regular working hours. The median door-to-balloon time is indicated. The boundaries of the box plots refer to the 25th and 75th percentiles, with the whisker bars representing the 5th and 95th percentiles.
Figure 3Meta-analysis of studies examining outcomes of primary percutaneous coronary intervention performed after hours and during regular working hours.
| Study | Overall N | Location | Inclusion criteria | Exclusion criteria | Working hours mortality | After-hours mortality | RR (95% CI) |
| Dominguez-Rodriguez | 90 | Spain, 2003 | Consecutive primary PCI, single centre | None identified | 1/51 (1.9%) in hospital | 5/39 (12.8%) | 6.54 (0.80 to 53.72) |
| Assali | 273 | Israel, 2001–2004 | Consecutive primary PCI, single centre | Cardiogenic shock | 2/160 (1.25%) in hospital 5/160 (3.1%) at 30 days | 7/113 (6.2%) 11/113 (9.7%) | 4.96 (1.05 to 23.42) |
| Ortolani | 985 | Italy, 2003–2005 | Consecutive primary PCI, single centre | Rescue PCI, in-hospital ST-segment elevation myocardial infarction | 29/382 (7.6%) in hospital | 49/603 (8.1%) | 1.06 (0.69 to 1.63) |
| Saleem | 1050 | USA, 1998–2002 | Consecutive primary PCI, single centre | 21/656 (3.2%) in hospital | 23/394 (5.8%) | 1.82 (1.02 to 3.25) | |
| Sadeghi | 2036 | International | CADILLAC randomized controlled trial, all sites 24/7 primary PCI | Shock, bleeding, renal insufficiency | 17/1047 (1.6%) at 30 days | 24/989 (2.4%) | 1.49 (0.81 to 2.76) |
| Henriques | 1702 | Netherlands, 1994–2000 | Consecutive primary PCI, within 6 h, single centre | Symptom onset >6 h | 17/909 (1.0%) at 30 days | 33/793 (4.2%) | 1.72 (1.18 to 2.51) |
| Magid | 33647 | USA, 1999–2002 | NRMI registry, PCI at 421 centres | Transfer patients | 728/15419 (4.7%) | 859/18228 (4.7%) in hospital | 1.0 (0.91 to 1.10) |
| Slonka | 1778 | Poland, 1998–2003 | Consecutive primary PCI, single centre, working hours defined as 0800–1500 | 33/482 (6.8%) in hospital | 80/1296 (6.2%) | 0.90 (0.61 to 1.33) | |
| Srimachochota | 256 | Thailand, 1999–2003 | Consecutive primary PCI, single centre | 11/107 (10.3%) in hospital | 16/149 (10.7%) | 1.04 (0.51 to 2.16) | |
| Zahn | 491 | Germany, 1994–1997 | MITRA registry, consecutive primary PCI at eight centres during the day and three centres at night (concern for selection bias—23% of patients done after-hours) | 33/378 (8.7%) in hospital | 6/113 (5.3%) | 0.61 (0.26 to 1.41) | |
| Garot | 288 | France | Consecutive primary PCI, <6 h after symptom onset, cath lab activated by cath lab staffed after hours by CCU nurses | Shock | 6/113 (5.3%) | 12/175 (6.9%) | 1.29 (0.50 to 3.34) |
| Graham | 2043 | Alberta, 1999–2006 | Consecutive primary PCI, three centres | Transfer patients | 32/896 (3.6%) | 57/1147 (5.0%) | 1.39 |
PCI, percutaneous coronary intervention.
| Model fit statistics | ||
| Criterion | Without covariates | With covariates |
| –2 log L | 1153.810 | 1050.941 |
| AIC | 1153.810 | 1090.941 |
| SBC | 1153.810 | 1138.075 |
| Testing global null hypothesis: beta=0 | |||
| Test | χ2 | df | Pr>χ2 |
| Likelihood ratio | 102.8685 | 20 | <0.0001 |
| Score | 148.7902 | 20 | <0.0001 |
| Wald | 120.9245 | 20 | <0.0001 |
| Analysis of maximum likelihood estimates | |||||||
| Parameter | df | Parameter estimate | SE | χ2 | Pr>χ2 | HR | 95% CI |
| After hour | 1 | 0.22990 | 0.24166 | 0.9050 | 0.3414 | 1.26 | 0.78 to 2.02 |
| Age | 1 | 0.41968 | 0.26344 | 2.5379 | 0.1111 | 1.52 | 0.91 to 2.55 |
| Sex | 1 | −0.62751 | 0.24654 | 6.4781 | 0.0109 | 0.53 | 0.33 to 0.87 |
| COPD | 1 | −0.05550 | 0.39203 | 0.0200 | 0.8874 | 0.95 | 0.44 to 2.04 |
| CEVD | 1 | 0.51473 | 0.38828 | 1.7574 | 0.1849 | 1.67 | 0.78 to 3.58 |
| Creat | 1 | 1.20996 | 0.38643 | 9.8038 | 0.0017 | 3.35 | 1.57 to 7.15 |
| Diabetes | 1 | 0.69557 | 0.26984 | 6.6446 | 0.0099 | 2.01 | 1.18 to 3.40 |
| Dialysis | 1 | −0.21161 | 0.71513 | 0.0876 | 0.7673 | 0.81 | 0.20 to 3.29 |
| HTN | 1 | −0.64629 | 0.25774 | 6.2878 | 0.0122 | 0.52 | 0.32 to 0.87 |
| Lipid | 1 | −1.04936 | 0.29260 | 12.8618 | 0.0003 | 0.35 | 0.20 to 0.62 |
| Liver/GI | 1 | 0.25309 | 0.64277 | 0.1550 | 0.6938 | 1.29 | 0.37 to 4.54 |
| Malignancy | 1 | −1.02538 | 1.02202 | 1.0066 | 0.3157 | 0.36 | 0.05 to 2.66 |
| Old MI | 1 | −0.15068 | 0.37330 | 0.1629 | 0.6865 | 0.86 | 0.41 to 1.79 |
| Lytic | 1 | −0.12468 | 0.72190 | 0.0298 | 0.8629 | 0.88 | 0.21 to 3.63 |
| PVD | 1 | 0.87345 | 0.36897 | 5.6040 | 0.0179 | 2.40 | 1.16 to 4.94 |
| Ef 35 | 1 | −0.51292 | 0.28934 | 3.1425 | 0.0763 | 0.60 | 0.34 to 1.06 |
| Ef 20 | 1 | 0.09989 | 0.40171 | 0.0618 | 0.8036 | 1.11 | 0.50 to 2.43 |
| Ef under20 | 1 | 1.08157 | 1.06411 | 1.0331 | 0.3094 | 2.95 | 0.37 to 23.74 |
| d1 | 1 | 0.83690 | 0.26202 | 10.2018 | 0.0014 | 2.31 | 1.38 to 3.86 |
| d2 | 1 | 1.39078 | 0.40562 | 11.7563 | 0.0006 | 4.02 | 1.81 to 8.90 |
| Model fit statistics | ||
| Criterion | Without covariates | With covariates |
| –2 log L | 1668.884 | 1528.640 |
| AIC | 1668.884 | 1568.640 |
| SBC | 1668.884 | 1623.187 |
| Analysis of maximum likelihood estimates | |||||||
| Parameter | df | Parameter estimate | SE | χ2 | Pr>χ2 | HR | 95% CI |
| After hour | 1 | 0.07764 | 0.19810 | 0.1536 | 0.6951 | 1.08 | 0.73 to 1.59 |
| Age | 1 | 0.72647 | 0.21061 | 11.8978 | 0.0006 | 2.07 | 1.37 to 3.12 |
| Sex | 1 | −0.49431 | 0.20938 | 5.5735 | 0.0182 | 0.61 | 0.41 to 0.92 |
| COPD | 1 | −0.40181 | 0.34744 | 1.3375 | 0.2475 | 0.67 | 0.34 to 1.32 |
| CEVD | 1 | 0.61525 | 0.31582 | 3.7951 | 0.0514 | 1.85 | 1.00 to 3.44 |
| Creat | 1 | 1.32714 | 0.31433 | 17.8261 | <0.0001 | 3.77 | 2.04 to 6.98 |
| Diabetes | 1 | 0.81857 | 0.21788 | 14.1147 | 0.0002 | 2.27 | 1.48 to 3.48 |
| Dialysis | 1 | −0.49067 | 0.61541 | 0.6357 | 0.4253 | 0.61 | 0.18 to 2.05 |
| HTN | 1 | −0.50147 | 0.21114 | 5.6409 | 0.0175 | 0.61 | 0.40 to 0.92 |
| Lipid | 1 | −0.67676 | 0.22209 | 9.2852 | 0.0023 | 0.51 | 0.33 to 0.79 |
| Liver/GI | 1 | 0.28563 | 0.49074 | 0.3388 | 0.5605 | 1.33 | 0.51 to 3.48 |
| Malignancy | 1 | 0.43663 | 0.44218 | 0.9750 | 0.3234 | 1.55 | 0.65 to 3.68 |
| Old MI | 1 | 0.05295 | 0.28561 | 0.0344 | 0.8529 | 1.05 | 0.60 to 1.85 |
| Lytic | 1 | −0.10150 | 0.59082 | 0.0295 | 0.8636 | 0.90 | 0.28 to 2.89 |
| PVD | 1 | 0.82531 | 0.31353 | 6.9289 | 0.0085 | 2.28 | 1.24 to 4.22 |
| Ef 35 | 1 | −0.58321 | 0.24534 | 5.6509 | 0.0174 | 0.56 | 0.35 to 0.90 |
| Ef 20 | 1 | 0.08877 | 0.33432 | 0.0705 | 0.7906 | 1.09 | 0.57 to 2.10 |
| Ef under20 | 1 | 0.37509 | 1.05195 | 0.1271 | 0.7214 | 1.46 | 0.19 to 11.44 |
| d1 | 1 | 0.78256 | 0.21761 | 12.9322 | 0.0003 | 2.19 | 1.43 to 3.35 |
| d2 | 1 | 1.44161 | 0.32632 | 19.5168 | <0.0001 | 4.23 | 2.23 to 8.01 |
COPD – chronic pulmonary disease
CEVD – cerebrovascular disease
HTN – hypertension
MI – myocardial infarction
Lytic – thrombolytic therapy
PVD – peripheral vascular disease
Ef – Ejection Fraction